Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes
Dexcom, a leader in continuous glucose monitoring (CGM), announced that the Dexcom G6 CGM System is now publicly covered by Alberta Health for children under 18 requiring insulin therapy. This initiative aims to enhance diabetes management for young patients, reducing A1C levels and the likelihood of hypoglycemic incidents. With this expansion, Alberta joins other jurisdictions providing CGM coverage, facilitating access to crucial diabetes technology. The system offers real-time glucose monitoring, alerts, and support for families managing their child's diabetes effectively.
- Public coverage of Dexcom G6 for under-18s improves access to diabetes management technology.
- Real-time monitoring enhances glycemic control and reduces hypoglycemia risk.
- Supports improved quality of life for young diabetes patients and their families.
- None.
- Dexcom CGM use is proven to improve glycemic control1,2and can reduce the risk of costly diabetes-related complications compared to fingerstick monitoring.3
The Dexcom G6 CGM System is now covered by
“We applaud the
The Dexcom G6 CGM System uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a display device; and a compatible smart device* or receiver that displays real-time glucose data to users without the need for calibration† or scanning. The Dexcom G6 CGM System provides users with real-time alerts, including a predictive Urgent Low Soon alert, and can warn the user in advance of hypoglycemia — giving them time to take appropriate action before it occurs. With the use of the Dexcom Follow App‡, parents and caregivers can also access their loved one’s glucose levels remotely and be alerted if they are going out of their target glucose range. As part of the
“In my practice, managing glucose through the use of real-time CGM has led to reduction in A1c, fewer incidences of hypoglycemia and an overall improvement in quality of life,” says Dr.
In 2021, the Diabetes Canada Clinical Practice Guidelines review committee updated its recommendations for glucose monitoring, stating that real-time CGM (rtCGM), like the Dexcom G6, should be used by individuals with type 1 diabetes treated with basal-bolus insulin injections or an insulin pump in order to reduce A1C and increase time in range, reduce duration and incidence of hypoglycemia and, in adults, improve quality of life.4
For more information about the coverage criteria for
About
† If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
* For a list of compatible devices, please visit dexcom.com/compatibility
‡ Following requires the Dexcom Follow App and an Internet connection. Followers should always confirm readings on the Dexcom G6 App or Receiver before making diabetes treatment decisions.
References
1 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.
2 Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2019;21(3):128-32.
3 Roze S, Isitt J,
4 Cheng AYY, Feig DS, Ho J, et al. Blood glucose monitoring in adults and children with diabetes: update 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005982/en/
Media Contact:
wagner@veritasinc.com
Source:
FAQ
What recent coverage did Dexcom receive from Alberta Health for the CGM system?
How does the Dexcom G6 CGM System benefit children with diabetes?
What is the significance of Alberta Health's coverage for Dexcom G6?
Which age group is eligible for the Dexcom G6 coverage from Alberta Health?